← Back to Screener
Sangamo Therapeutics, Inc. Common Stock (SGMO)
Price$0.21
Value ScoreC
Growth ScoreF
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-61.29%
Price vs S&P 500 (4W)86.97%
VGM Score32.37
Market Capitalization$89.07M
All Metrics
Book Value / Share (Quarterly)$0.02
P/TBV (Annual)9.35x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-29.17%
Cash Flow / Share (Quarterly)$-0.22
Price vs S&P 500 (YTD)-56.97%
Net Profit Margin (TTM)-356.89%
EPS (TTM)$-0.38
10-Day Avg Trading Volume3.16M
EPS Excl Extra (TTM)$-0.38
Revenue Growth (5Y)-19.66%
EPS (Annual)$-0.44
ROI (Annual)-430.13%
Net Profit Margin (5Y Avg)-192.08%
Cash / Share (Quarterly)$0.07
Revenue Growth QoQ (YoY)-77.60%
ROA (Last FY)-205.76%
Revenue Growth TTM (YoY)-45.80%
EBITD / Share (TTM)$-0.37
ROE (5Y Avg)-175.64%
Operating Margin (TTM)-357.55%
Cash Flow / Share (Annual)$-0.28
P/B Ratio14.27x
P/B Ratio (Quarterly)32.54x
Net Income / Employee (Annual)$-865,700
EV / Revenue (TTM)1.78x
Net Interest Coverage (TTM)-222.00x
ROA (TTM)-161.26%
EPS Incl Extra (Annual)$-0.44
Current Ratio (Annual)0.84x
Quick Ratio (Quarterly)0.64x
3-Month Avg Trading Volume9.15M
52-Week Price Return-56.30%
Revenue / Employee (TTM)$243,400
Tangible BV / Share (Quarterly)$0.11
P/S Ratio (Annual)2.25x
Asset Turnover (Annual)0.66x
52-Week High$0.77
Operating Margin (5Y Avg)-197.67%
EPS Excl Extra (Annual)$-0.44
CapEx CAGR (5Y)-63.00%
Tangible BV CAGR (5Y)-43.03%
26-Week Price Return-53.36%
Quick Ratio (Annual)0.74x
13-Week Price Return-42.96%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.70x
Enterprise Value$61.49M
Revenue / Share Growth (5Y)-30.64%
Asset Turnover (TTM)0.45x
Book Value / Share Growth (5Y)-50.84%
Revenue / Employee (Annual)$278,500
Pretax Margin (Annual)-312.25%
Cash / Share (Annual)$0.06
3-Month Return Std Dev176.05%
Net Income / Employee (TTM)$-868,500
ROE (Last FY)-430.13%
EPS Basic Excl Extra (Annual)$-0.44
P/FCF (TTM)7.65x
Receivables Turnover (TTM)55.78x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.38
Receivables Turnover (Annual)88.19x
ROI (TTM)-813.95%
P/S Ratio (TTM)2.58x
Pretax Margin (5Y Avg)-192.86%
Revenue / Share (Annual)$0.14
Tangible BV / Share (Annual)$0.11
Price vs S&P 500 (52W)-80.67%
Year-to-Date Return-48.81%
5-Day Price Return1.80%
EPS Normalized (Annual)$-0.44
ROA (5Y Avg)-103.40%
Net Profit Margin (Annual)-310.81%
Month-to-Date Return-1.24%
Cash Flow / Share (TTM)$-1.36
EBITD / Share (Annual)$-0.42
Operating Margin (Annual)-306.53%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-175.64%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.38
P/TBV (Quarterly)9.35x
P/B Ratio (Annual)9.35x
Pretax Margin (TTM)-358.88%
Book Value / Share (Annual)$0.11
Price vs S&P 500 (13W)-51.21%
Beta1.33x
P/FCF (Annual)0.57x
Revenue / Share (TTM)$0.09
ROE (TTM)-813.95%
52-Week Low$0.10
vGradeC
gGradeF
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.08est. 0.01
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.00
4.00
4.00
4.00
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SGMOSangamo Therapeutics, Inc. Common Stock | C | F | D | $0.21 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Sangamo Therapeutics is a genomic medicine company developing gene-based therapies for serious genetic and neurological diseases. Its pipeline includes programs in neurology (chronic neuropathic pain, prion disease, ALS, FTD, Huntington's disease), hematology (hemophilia A), and other indications including Fabry disease and multiple sclerosis, with several programs advanced through partnerships.